Baseline type 2 biomarker levels and response to tezepelumab in severe asthma

BACKGROUND: Tezepelumab is a human monoclonal antibody that blocks activity of thymic stromal lymphopoietin (TSLP). In the phase IIb PATHWAY study (NCT02054130), tezepelumab significantly reduced annualized asthma exacerbation rates (AAERs) versus placebo in adults with severe, uncontrolled asthma....

Descripción completa

Detalles Bibliográficos
Autores principales: Corren, Jonathan, Pham, Tuyet‐Hang, Garcia Gil, Esther, Sałapa, Kinga, Ren, Pin, Parnes, Jane R., Colice, Gene, Griffiths, Janet M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306691/
https://www.ncbi.nlm.nih.gov/pubmed/34913186
http://dx.doi.org/10.1111/all.15197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306691/
https://www.ncbi.nlm.nih.gov/pubmed/34913186
http://dx.doi.org/10.1111/all.15197

Ejemplares similares